SPT2DSistema de Páncreas Biónico Solo con Insulina para el Manejo de la Diabetes Tipo 2

This study focuses on Type 2 Diabetes and aims to evaluate the safety and effectiveness of an insulin-only bionic pancreas system. This system is set at a specific point of 100 mg/dl. The study involves individuals who have Type 2 Diabetes. The main goal is to understand if this system can help improve blood sugar control, which is a common challenge in managing this condition. The study could potentially lead to better care and treatment options for people living with Type 2 Diabetes. The study is divided into two parts, each lasting for 7 days. One part involves usual care, while the other part involves using the insulin-only bionic pancreas system. The study measures the average blood sugar level and the time spent with low blood sugar levels, specifically less than 54 mg/dl. These measurements are taken from a device called Dexcom CGM and are collected during the last five days of each part. This is done to predict potential outcomes for long-term use. The first two days are not included to allow for the clearance of long-acting insulins.